Table 1.
Association of biomarkers with clinicopathological parameters in the SJRH cohort
| FOSL2 | P value | ATP1B1 | P value | STMN2 | P value | TRIM14 | P value | |||||
| Characteristics | High (n=125) | Low (n=43) | High (n=32) | Low (n=142) | High (n=59) | Low (n=112) | High (n=50) | Low (n=41) | ||||
| Age, years | 0.85 | 0.68 | 0.01 | 0.66 | ||||||||
| <65 | 39 (31.2%) | 14 (32.6%) | 9 (28.1%) | 46 (32.4%) | 11 (18.6%) | 42 (37.5%) | 19 (38.0%) | 13 (31.7%) | ||||
| ≥65 | 86 (68.8) | 29 (67.4%) | 23 (78.9%) | 96 (67.6%) | 48 (81.4%) | 70 (62.5%) | 31 (62.0%) | 28 (68.3%) | ||||
| Sex | 0.22 | 0.12 | 0.34 | 0.29 | ||||||||
| Male | 61 (48.8%) | 26 (60.5%) | 12 (37.5%) | 77 (54.2%) | 27 (45.8%) | 60 (53.6%) | 26 (52.0%) | 16 (39.1%) | ||||
| Female | 64 (51.2%) | 17 (39.5%) | 20 (62.5%) | 66 (46.4%) | 32 (54.2%) | 52 (46.4%) | 24 (48.0%) | 25 (60.9%) | ||||
| TNM stage | 0.38 | 0.29 | 0.1 | 0.79 | ||||||||
| I | 74 (59.2%) | 30 (69.8%) | 18 (56.2%) | 90 (63.4%) | 43 (72.9%) | 63 (56.3%) | 34 (68.0%) | 26 (63.4%) | ||||
| II | 33 (26.4%) | 7 (16.3%) | 11 (34.4%) | 31 (21.8%) | 10 (16.9%) | 31 (27.7%) | 10 (20.0%) | 8 (19.5%) | ||||
| III | 18 (14.4%) | 6 (13.9%) | 3 (9.4%) | 21 (14.8%) | 6 (10.2%) | 18 (16.0%) | 6 (12.0%) | 7 (17.1%) | ||||
| Histology | 0.5 | 0.64 | 0.29 | 0.2 | ||||||||
| Adeno | 64 (51.2%) | 21 (48.8%) | 14 (43.8%) | 72 (50.7%) | 29 (49.2%) | 56 (50.0%) | 29 (58.0%) | 16 (39.1%) | ||||
| SCC | 44 (25.2%) | 13 (30.2%) | 11 (34.3%) | 47 (33.1%) | 17 (28.8%) | 41 (36.6%) | 16 (32.%) | 19 (46.3%) | ||||
| Other | 17 (13.6%) | 9 (20.9%) | 7 (21.9%) | 22 (15.5%) | 13 (22.0%) | 15 (13.4%) | 5 (10.0%) | 6 (14.6%) | ||||
| Type of surgery | 1 | 0.7 | 0.75 | 1 | ||||||||
| Pneumonectomy | 9 (7.2%) | 3 (7.0%) | 1 (3.1%) | 11 (7.7%) | 5 (8.5%) | 7 (6.3%) | 3 (6.0%) | 3 (7.3%) | ||||
| Lesser surgery | 116 (92.8%) | 40 (93.0%) | 31 (96.9%) | 131 (92.3%) | 54 (91.5%) | 105 (93.7%) | 47 (94.0%) | 38 (92.7%) | ||||
| Chemotherapy | 0.02 | 0.47 | 0.63 | 0.68 | ||||||||
| Post | 44 (35.2%) | 9 (20.9%) | 8 (25.0% | 47 (33.1%) | 16 (27.1%) | 39 (34.8%) | 15 (30.0%) | 9 (22.0%) | ||||
| None | 77 (61.6%) | 28 (65.1%) | 21 (65.6%) | 88 (62.0%) | 39 (66.1%) | 67 (59.8%) | 32 (64.0)% | 29 (70.7%) | ||||
| Other | 4 (3.2%) | 6 (14.5%) | 3 (9.4%) | 7 (4.9%) | 4 (6.8%) | 6 (5.4%) | 3 (6.0%) | 3 (7.3%) | ||||
| KRAS mutation | 0.24 | 0.51 | 0.37 | 0.63 | ||||||||
| Present | 33 (26.4%) | 16 (37.2%) | 7 (21.9%) | 41 (28.9%) | 14 (23.7%) | 35 (31.2%) | 14 (28.0%) | 9 (22.0%) | ||||
| Absent | 92 (73.6%) | 27 (62.8%) | 25 (78.1%) | 101 (71.1%) | 45 (76.3%) | 77 (68.8%) | 36 (72.0%) | 32 (78.0%) | ||||
*Bold values represent statistical significance
adeno, adenocarcinoma; SCC, squamous cell carcinoma; SJRH, Saint John Regional Hospital.